$46.45
+0.85 (+1.86%)
Open$46.47
Previous Close$45.60
Day High$47.73
Day Low$45.75
52W High$48.03
52W Low$15.86
Volume—
Avg Volume863.8K
Market Cap2.29B
P/E Ratio—
EPS$-1.98
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
-2.3% upside
Current
$46.45
$46.45
Target
$45.36
$45.36
$37.53
$45.36 avg
$61.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 112.36M | 94.04M | 574.93M |
| Net Income | -157,092,041 | -118,331,801 | 29.33M |
| Profit Margin | -139.8% | -132.8% | 5.1% |
| EBITDA | -127,476,934 | -101,358,459 | 65.79M |
| Free Cash Flow | — | — | 30.48M |
| Rev Growth | +19.5% | +19.5% | -7.8% |
| Debt/Equity | — | — | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |